This proposal describes the facilities and services to be provided by the Viral Immunology Core of the NYU CFAR. The primary purpose of this Core is a) Provision of a range of assays to measure the function and characteristics of various cells involved in immune defense against HIV, the function of cells affected by HIV infection, and, the HLA type of cells (when this information is needed to perform various cellular assays);b) Testing of polyclonal sera as well as human, primate and rodent anti-HIV monoclonal antibodies (mAbs) for anti-HIV activity, for neutralizing activity against a wide range of HIV primary isolates, and for their ability to bind to intact virions and to infected cells;c) Virus isolation and characterization so that these viruses can be used in the aforementioned immunologic assays;d) Construction and production of pseudoviruses for use in the aforementioned assays;e) Provision of human anti-HIV mAbs to CFAR investigators and AIDS researchers around the world;f) Sequencing of Ig and T cell receptor genes for studies of gene usage in immune responses in the setting of HIV infection;and g) Provision of training to investigators, students, postdocs, international fellows, Infectious Disease fellows, and technicians, within and outside of CFAR, in the techniques enumerated above. The services of this core are available to the NYU AIDS research community, to NYU researchers in other fields (such as members of the NYU Cancer Center), to NIH supported researchers outside of NYU, and to those scientists around the world who need mAbs for meritorious HIV-related projects. A charge-back system is in place and contributes to the support of the services provided.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Center Core Grants (P30)
Project #
5P30AI027742-20
Application #
7935352
Study Section
Special Emphasis Panel (ZAI1)
Project Start
Project End
2012-06-30
Budget Start
2009-07-01
Budget End
2012-06-30
Support Year
20
Fiscal Year
2009
Total Cost
$389,223
Indirect Cost
Name
New York University
Department
Type
DUNS #
121911077
City
New York
State
NY
Country
United States
Zip Code
10016
Gornalusse, German G; Mummidi, Srinivas; Gaitan, Alvaro A et al. (2015) Epigenetic mechanisms, T-cell activation, and CCR5 genetics interact to regulate T-cell expression of CCR5, the major HIV-1 coreceptor. Proc Natl Acad Sci U S A 112:E4762-71
Miller, Elizabeth A; Gopal, Ramya; Valdes, Vanessa et al. (2015) Soluble CD40 ligand contributes to dendritic cell-mediated T-cell dysfunction in HIV-1 infection. AIDS 29:1287-96
Phelan, Joan A; Abrams, William R; Norman, Robert G et al. (2014) Design aspects of a case-control clinical investigation of the effect of HIV on oral and gastrointestinal soluble innate factors and microbes. PLoS One 9:e112901
Sivapalasingam, Sumathi; Mendillo, Megan; Ahmed, Aabid et al. (2014) The importance of caregivers in the outcome of pediatric HIV management, Mombasa, Kenya. AIDS Care 26:425-33
Weiden, Michael D; Hoshino, Satomi; Levy, David N et al. (2014) Adenosine deaminase acting on RNA-1 (ADAR1) inhibits HIV-1 replication in human alveolar macrophages. PLoS One 9:e108476
Ryndak, Michelle B; Singh, Krishna K; Peng, Zhengyu et al. (2014) Transcriptional profiling of Mycobacterium tuberculosis replicating ex vivo in blood from HIV- and HIV+ subjects. PLoS One 9:e94939
Weiser, Keren; Barton, Meredith; Gershoony, Dafna et al. (2013) HIV's Nef interacts with ?-catenin of the Wnt signaling pathway in HEK293 cells. PLoS One 8:e77865
O'Brien, Meagan; Montenont, Emilie; Hu, Liang et al. (2013) Aspirin attenuates platelet activation and immune activation in HIV-1-infected subjects on antiretroviral therapy: a pilot study. J Acquir Immune Defic Syndr 63:280-8
Rich, Josiah D; DiClemente, Ralph; Levy, Judith et al. (2013) Correctional facilities as partners in reducing HIV disparities. J Acquir Immune Defic Syndr 63 Suppl 1:S49-53
Alvarez, Yelina; Tuen, Michael; NĂ das, Arthur et al. (2012) In vitro restoration of Th17 response during HIV infection with an antiretroviral drug and Th17 differentiation cytokines. AIDS Res Hum Retroviruses 28:823-34

Showing the most recent 10 out of 254 publications